Compare Adaptive Biotechnologies Corp (ADPT) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.65. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | LQD | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $112.91 |
52-Week Low | $10.24 | $107.12 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, is trading at $108.67, showing minimal daily change. The technical outlook is bearish based on moving averages, though short-term oscillators like the RSI suggest potential oversold conditions. Recent news highlights strong investor flows into bond ETFs amid market uncertainty and rate hike speculation, positioning LQD as a core vehicle for investment-grade corporate bond exposure.
The outlook for LQD is tied to interest rate expectations and corporate credit health. The primary opportunity lies in its role as a liquid, diversified source of investment-grade yield, especially if rate hikes pause. Key risks include rising interest rates pressuring bond prices and potential credit spread widening if economic conditions deteriorate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
